At present, there are about 84,000 new lymphoma patients in China every year, and the rate of increase is 5% per year [2]. More seriously, in recent years, lymphoma has become more and more “favored” by young people, and the incidence trend is becoming younger. When it comes to this systemic malignant disease involving the immune system, the first reaction of the majority of people is that the disease is equivalent to a terminal disaster. The lymphatic system is an important defense system of the body and is often referred to as the human “guard”. However, lymphatic tissues can be separated from the body’s control and become “bad elements”. When there are more and more “bad molecules” and factors such as bad environment, lymphocytes may mutate during the growth process and form crazy lymphoma. However, “lymphoma” is not a disease, but a group of malignant diseases with various manifestations and essences, which can be divided into two types: Hodgkin’s lymphoma and non-Hodgkin’s lymphoma, with the latter accounting for about 90%. Among non-Hodgkin’s lymphoma, about 3 percent of them become diffuse large B-cell lymphoma. Compared with other types of lymphoma, these patients have faster tumor progression and higher malignancy, which can progress rapidly within six months to a year, making treatment more difficult. Although diffuse large B-cell lymphoma is difficult to treat, it does not mean that we are “helpless” to do so. Internationally, it has been reported that “immunotherapy (melphalan) combined with chemotherapy regimens are now significantly improving the outcome of patients with diffuse large B-cell lymphoma. The study showed that by adhering to the standard treatment of 8 courses, 76% of patients had complete tumor remission, while the follow-up of 10 years found that 58% of patients were cured and more than 40% of patients could obtain 10-year long-term survival. Don’t neglect regular review After completing the standard treatment program, can lymphoma patients rest easy? The answer is no. Although after receiving standard treatment, patients’ disease is controlled and about 60% of patients are cured, but after treatment patients will face a series of problems such as physical and psychological recovery after anti-tumor treatment, potential long-term complications, and return to family and society. Therefore, lymphoma patients need to be followed up every 3 months for the first 2 years after the end of treatment, and then once every 6 months to once a year for the rest of their lives, so as to ensure a better survival.